Aug 21, 2024
In this podcast episode, Tom McCourt, chief
executive officer of Ironwood Pharmaceuticals, discusses the
evolving relationship between physicians and pharma, breakthroughs
in GI drugs and more.
• Intro :59
• Welcome to this episode of Gut Talk
1:23
• The interview/about McCourt
1:32
• Tell us about your family and where you grew up.
2:15
• What did you take away from your football career at
University of Wisconsin? 4:19
• How long were you a clinical pharmacist?
7:57
• McCourt on his experience as a health science
associate. 8:55
• Where is the line between academics and the pharma
industry? 10:49
• When you launched drugs like omeprazole and
esomeprazole, did you have any idea what impact they would have?
13:00
• What changed to make the pharma industry go from
respected to villainized? 16:39
• What’s your perspective on innovation and billing
architecture for pharmaceuticals? […] Where do you think we’re
going to see the most exciting changes in the near-term?
19:33
• Chey and McCourt on challenges the US health care
system faces in comparison to other countries.
24:47
• How can we make breakthrough drugs and technology
available to everyone without stifling innovation?
27:05
• Did patients valuing their quality-of-life factor
into your decision to switch from AmGen to Ironwood
Pharmaceuticals? 29:12
• From a pharmaceutical perspective, do you think
there are examples of successful health policy?
36:30
• Thank you, Tom 42:13
• Thanks for listening
43:20
Tom McCourt is the chief executive officer of
Ironwood Pharmaceuticals, a commercial biotechnology company
working to revolutionize the treatment of gastrointestinal (GI)
diseases and redefine the standard of care for millions of
patients.
We’d love to hear from you! Send your comments/questions to
guttalkpodcast@healio.com.
Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from
McCourt, follow @ironwoodpharma on X.
Disclosures: Berry and Chey report no relevant
financial disclosures. McCourt is chief executive officer and a
member of the board of directors of Ironwood Pharmaceuticals;
serves on the board of directors and member of the compensation
committee of Pliant Therapeutics, Inc., a public company, and on
the board of trustees for the American Society of Gastrointestinal
Endoscopy (ASGE).